Peptide · Approved

Liraglutide

A daily GLP-1 receptor agonist for type-2 diabetes (Victoza) and weight management (Saxenda). Prescription-only.

Key facts

  • Also known as: Victoza, Saxenda
  • Status: Approved
  • Used for: Diabetes, weight loss (GLP-1)
  • Natural counterpart: Mimics natural GLP-1, the incretin released by gut L-cells after eating.
  • Target enzyme / receptor: GLP-1 receptor (GLP-1R) — class B GPCR
  • Signalling pathway: Gαs → adenylate cyclase → cAMP → PKA → glucose-dependent insulin secretion
    In plain terms: Boosts insulin only when blood sugar is high, slows the stomach, and dials down appetite.
  • Crystal / cryo-EM structure: Available  PDB 5VAI ↗

Status & safety

This is an approved medicine — prescription-only in most countries. Only use it under a licensed clinician, obtained through a pharmacy.

Research & clinical studies

Explore the biochemistry and clinical evidence for Liraglutide — these open live, date-sorted searches, so they always show the latest.

Read research papers on PubMed ↗

Clinical studies (ClinicalTrials.gov) ↗ Google Scholar ↗ Related guide → All peptides & profiles →

Not medical advice. Chemdu is an educational resource and does not sell, prescribe or supply any peptide. Consult a licensed professional about any medicine or supplement.